Key Points
- Xenon Pharmaceuticals insider Christopher John Kenney sold 7,068 shares for $425,847 at an average price of $60.25. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with two shares.
- XENE shares opened at $60.00, with a market capitalization of approximately $5.8 billion. The company reported a quarterly loss of $1.11 per share, beating analysts’ expected loss of $1.16.
- Institutional investors own 95.45% of Xenon’s stock, while analysts maintain a generally positive outlook: the shares have an average “Buy” rating and a consensus price target of $77.13.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) insider Christopher John Kenney sold 7,068 shares of the business's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the sale, the insider owned 2 shares in the company, valued at $120.50. The trade was a 99.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Xenon Pharmaceuticals Trading Down 0.4%
Shares of Xenon Pharmaceuticals stock opened at $60.00 on Wednesday. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of -12.66 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 12-month low of $35.60 and a 12-month high of $72.66. The firm's 50 day simple moving average is $63.40 and its two-hundred day simple moving average is $56.73.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.05. During the same period in the previous year, the business posted ($1.07) earnings per share. On average, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.
Hedge Funds Weigh In On Xenon Pharmaceuticals
Large investors have recently made changes to their positions in the stock. Corient Private Wealth LP lifted its stake in Xenon Pharmaceuticals by 1.5% during the second quarter. Corient Private Wealth LP now owns 28,732 shares of the biopharmaceutical company's stock worth $1,734,000 after purchasing an additional 430 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Xenon Pharmaceuticals by 5,935.5% in the 2nd quarter. California State Teachers Retirement System now owns 5,597,786 shares of the biopharmaceutical company's stock valued at $337,882,000 after buying an additional 5,505,039 shares during the period. Headlands Technologies LLC grew its holdings in Xenon Pharmaceuticals by 377.0% during the 2nd quarter. Headlands Technologies LLC now owns 29,194 shares of the biopharmaceutical company's stock worth $1,762,000 after acquiring an additional 23,074 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Xenon Pharmaceuticals during the second quarter worth $206,000. Finally, Hsbc Holdings PLC increased its holdings in shares of Xenon Pharmaceuticals by 24.6% in the 2nd quarter. Hsbc Holdings PLC now owns 151,474 shares of the biopharmaceutical company's stock valued at $9,143,000 after acquiring an additional 29,916 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts recently commented on XENE shares. HC Wainwright reaffirmed a "buy" rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Wells Fargo & Company reaffirmed an "overweight" rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Wall Street Zen raised shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an "overweight" rating in a report on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $77.13.
Get Our Latest Stock Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
